ChromaDex Reports Record Revenue as Ingredients Sales Climb 83% Compared to Previous Year Period
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
ChromaDex (CDXC) Receives FDA GRAS No Objection Letter for NIAGEN
August 15, 2016 6:32 AM EDTChromaDex Corp. (Nasdaq: CDXC) announced that the U.S. Food and Drug Administration (FDA) has issued a generally recognized as safe (GRAS) No Objection Letter, in response to the NIAGEN® nicotinamide riboside chloride (NR) GRAS filing, Notice No. GRN 000635.
Receipt of... More
ChromaDex (CDXC) Reports Q2 EPS of $0.00
August 11, 2016 4:41 PM EDTChromaDex (NASDAQ: CDXC) reported Q2 EPS of $0.00, versus ($0.01) reported last year. Revenue for the quarter came in at $8.8 million, versus $6.1 million reported last year.
For earnings history and earnings-related data on ChromaDex (CDXC) click here.
... More